Sofosbuvir and Ribavirin in Turkish non-cirrhotic chronic hepatitis C patients infected with genotype 2 or 3

Aim: Few studies have evaluated real-world clinical experience with sofosbuvir (SOF) plus ribavirin (RBV) in hepatitis C virus (HCV)genotypes 2 and 3 infections from Turkey. Thus, this study aimed to investigate the results of sofosbuvir plus ribavirin therapy ingenotype 2 and 3 cases followed in an infectious disease clinic at a university hospital in Hatay, southern Turkey.Material and Methods: In this single-centre, retrospective, observational study, 58 eligible patients treated with SOF/RBV (400 mgof SOF plus weight-based RBV) therapy between October 2016 and February 2019 were examined. Forty-three patients who hadcompleted the duration of treatment and had known virological response status were evaluated for treatment outcomes.Results: SOF/RBV achieves a sustained virological response (SVR) rate of 96.3% and 100% in the HCV genotype 2 and 3 groups,respectively, with treatment duration of 12-24 weeks. No patient experienced a virologic breakthrough while only one experiencedvirologic relapse after the completion of therapy. The incidence of adverse events was 25.5% (11/43) while the most common(11.6%) adverse event was ribavirin-related hemolytic anemia.Conclusion: The current study revealed that the SOF/RBV therapy achieved excellent response rates with a good safety profile innon-cirrhotic Turkish patients infected with HCV genotype 2 or 3.

PDF

___

1. World Health Organization. WHO model list of essential medicines. Retrieved February 12, 2020, from https://www.who.int/medicines/publications/ essentialmedicines/en/
2. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61:45-57.
3. Çetin Duran A, Kaya Çetinkaya Ö, Sayıner AA, et al. Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data. Turk J Gastroenterol 2020;31:128-35.
4. Robaeys G, Bielen R, Azar DG, et al. Global genotype distribution of hepatitis C viral infection among people who inject drugs. J Hepatol 2016;65:1094-103.
5. Edlin BR, Carden MR. Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 2006;42:673-6.
6. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
7. Welzel TM, Nelson DR, Morelli G, et al. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Gut 2017;66:1844-52.
8. Tsai WL, Wang CF, Cheng JS, et al. Sofosbuvirbased r egimen for genotype 2 HCV infected patients in Taiwan: A real World experience. PLoS One 2020;15:e0227424.
9. Kurtaran B, Sarıgül F, Çabalak M, et al. Efficacy and safety of direct-acting antivirals in chronic hepatitis C patients infected with genotype 2 and 3 in Turkey. AASLD-TASL Connect Regional Meeting, 15-16 March, 2019. İstanbul, Turkey, 59-60.
10. Örmeci N, Gülşen MT, Sezgin O, et al. Treatment of HCV infection with direct-acting antiviral agents. Real life experiences from the Euro-Asian region. Turk J Gastroenterol. 2020;31:148-55.
11. Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014;21:762-8.
12. Wehmeyer MH, Ingiliz P, Christensen S, et al. Realworld effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03). J Med Virol 2018;90:304-12.
13. Huang R, Rao H, Xie Q, et al. Comparison of the efficacy of sofosbuvir plus ribavirin in Chinese patients with genotype 3a or 3b HCV infection. J Med Virol 2019;91:1313-8.
14. Su F, Green PK, Berry K, et al. The association between race/ethnicity and the effectiveness of direct acting antiviral agents for hepatitis C virus infection. Hepatology 2016;65:426-38.
15. Lu M, Wu KH, Li J, et al. Adjuvant ribavirin and longer direct-acting antiviral treatment duration improve sustained virological response among hepatitis C patients at risk of treatment failure. J Viral Hepat 2019;26:1210-7.
16. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Eng J Med 2013;368:34-44.
17. Chen CH, Yu ML. Evolution of interferon-based therapy for chronic Hepatitis C. Hepat Res Treat 2010;2010:140953.
18. Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferonalfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology 2015;149:1462-70.
19. Kattakuzhy S, Levy R, Rosenthal E, et al. Hepatitis C genotype 3 disease. Hepatol Int 2016;10:861-70.
20. Chan A. Genotype 3 Infection-The last stand of hepatitis C virus. Drugs 2017;77:131-44.
21. Cho Y, Cho EJ, Lee JH, et al. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Clin Mol Hepatol 2015;21:358-64.
22. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
23. Sulkowski MS, Cooper C, Hunyady B, et al. Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011;8:212-3.
24. Ahn SH, Lim YS, Lee KS, et al. A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus. J Viral Hepat 2016;23:358-65.
25. Cornberg M, Petersen J, Schober A, et al. Real-world use, effectiveness and safety of antiviral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther 2017;45:688-700.
26. Atsukawa M, Tsubota A, Kondo C, et al. Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Dig Liver Dis 2017;49:1029-35.
27. Kao JH, Chien RN, Chang TT, et al. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. Liver Int 2016;36:1101-7.
28. Chen CC, Tung SY, Wei KL, et al. Incidence, risk factors and impact on virological response of anemia in chronic genotype 2 hepatitis C receiving sofosbuvir plus ribavirin. J Formos Med Assoc 2020;119:532-7.